ReviewCureus2025
Evolution of the Global Landscape of Nanoparticles and Nanotubes in Advancing Oncological Care: A Bibliometric Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to analyze the literature published regarding nano-oncology and, more specifically, global trends concerning nanoparticles and nanotubes from 2003 to 2025. This bibliometric analysis gathered data from the Web of Science Core Collection, incorporating keywords such as oncology, nanotechnology, nanomedicine, nanoparticles, and nanotubes. With the retrieved data visualized in the VOSViewer program and Web of Science Core Collection, the primary focus was on keywords, countries, and organizations, from 1,465 total documents. Analysis indicates that research has increased recently because of the development of nanotechnologies, particularly through drug delivery and imaging mechanisms. The United States, the People's Republic of China, and India were the most prevalent publishers, often collaborating with other countries to focus on an integrated global community with similar nanotechnological interests based on shared challenges. Overall, this analysis highlights the continuously evolving field of nano-oncology and how these advancements will reshape global cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.